ClinicalTrials.gg
CompletedNCT05644353Updated Mar 28, 2025Results posted

A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy Participants

A Phase 1 interventional study of Mirikizumab in Healthy, sponsored by Eli Lilly and Company. Completed at 6 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-28.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The main purpose of this study is to evaluate amount of mirikizumab (test) that gets into the blood stream and how long it takes the body to get rid of it, when given via pre-filled syringe compared to mirikizumab (reference) solution given via pre-filled syringe. The information about any adverse effects experienced will be collected and the tolerability of mirikizumab will also be evaluated.

Screening is required within 35 days prior to enrolment. For each participant, the total duration of the clinical trial will be about 17 weeks including screening.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are overtly healthy as determined by medical evaluation
  • Have a ( BMI) within the range of 18.0 to 34.0 kg/m2, inclusive.
  • Are males or non-pregnant women of (WOCBP) or women not of childbearing potential (WNOCBP).

Exclusion criteria

Exclusion Criteria:

  • Have significant allergies to humanized monoclonal antibodies or known allergies to mirikizumab, related compounds or any components of the formulation, or history of significant atopy
  • Have an abnormal blood pressure, pulse rate, or temperature as determined by the investigator
  • Intend to use over-the-counter or prescription medication, including herbal medications and traditional medications, within 7 days prior to dosing
  • Are lactating or pregnant
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
450 participants (actual)

Study arms

  • Experimental
    Mirikizumab

    Participants received 3 milliliter (mL) mirikizumab as 2 subcutaneous (SC) injections of 1 mL and 2 mL delivered via Pre-filled Syringe (PFS) to abdomen or arms or thighs on Day 1.

    Drug: Mirikizumab

  • Experimental
    Citrate-Free Mirikizumab

    Participants received 3 mL citrate- free mirikizumab as 2 SC injections of 1 mL and 2 mL delivered via PFS to abdomen or arms or thighs on Day 1.

    Drug: Mirikizumab

Interventions

  • Administered SC.

    Also known as: LY3074828

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab in a Citrate-free Solution Formulation Compared to the Solution Formulation

    PK: Cmax of Mirikizumab

    Time frame: Pre-dose, 72, 120, 192, 264, 360, 528, 696, 1032, 1368, 1704 and, 2040 hours post day 1 dose

  2. PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Mirikizumab in a Citrate-free Solution Formulation Compared to the Solution Formulation

    PK: AUC\[0-∞\] of Mirikizumab

    Time frame: Pre-dose, 72, 120, 192, 264, 360, 528, 696, 1032, 1368, 1704 and, 2040 hours post day 1 dose

  3. PK: Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Mirikizumab in a Citrate-free Solution Formulation Compared to the Solution Formulation

    PK: AUC\[0-tlast\] of Mirikizumab

    Time frame: Pre-dose, 72, 120, 192, 264, 360, 528, 696, 1032, 1368, 1704 and, 2040 hours post day 1 dose

07

Results

Posted Mar 28, 2025

Participant flow

Participant flow — Overall Study
MilestoneMirikizumab - AbdomenMirikizumab - ArmMirikizumab - ThighCitrate-Free Mirikizumab - AbdomenCitrate-Free Mirikizumab - ArmCitrate-Free Mirikizumab - Thigh
Started747676757574
Received at least one dose of study drug747676757574
Completed727475757474
Not completed221010
Withdrew: Physician decision100000
Withdrew: Protocol violation100000
Withdrew: Withdrawal by subject020010
Withdrew: Lost to follow-up001000

Outcome measures

PrimaryPharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab in a Citrate-free Solution Formulation Compared to the Solution Formulation

PK: Cmax of Mirikizumab

Time frame:
Pre-dose, 72, 120, 192, 264, 360, 528, 696, 1032, 1368, 1704 and, 2040 hours post day 1 dose
Reported as:
Geometric mean · micrograms per milliliter (μg/mL)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab in a Citrate-free Solution Formulation Compared to the Solution Formulation
micrograms per milliliter (μg/mL)MirikizumabCitrate-Free Mirikizumab
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab in a Citrate-free Solution Formulation Compared to the Solution Formulation20.9 ± 4320.9 ± 39
PrimaryPK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Mirikizumab in a Citrate-free Solution Formulation Compared to the Solution Formulation

PK: AUC\[0-∞\] of Mirikizumab

Time frame:
Pre-dose, 72, 120, 192, 264, 360, 528, 696, 1032, 1368, 1704 and, 2040 hours post day 1 dose
Reported as:
Geometric mean · microgram*day per milliliter (μg*day/ mL
PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Mirikizumab in a Citrate-free Solution Formulation Compared to the Solution Formulation
microgram*day per milliliter (μg*day/ mLMirikizumabCitrate-Free Mirikizumab
PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Mirikizumab in a Citrate-free Solution Formulation Compared to the Solution Formulation331 ± 39325 ± 36
PrimaryPK: Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Mirikizumab in a Citrate-free Solution Formulation Compared to the Solution Formulation

PK: AUC\[0-tlast\] of Mirikizumab

Time frame:
Pre-dose, 72, 120, 192, 264, 360, 528, 696, 1032, 1368, 1704 and, 2040 hours post day 1 dose
Reported as:
Geometric mean · microgram*day per milliliter (μg*day/ mL
PK: Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Mirikizumab in a Citrate-free Solution Formulation Compared to the Solution Formulation
microgram*day per milliliter (μg*day/ mLMirikizumabCitrate-Free Mirikizumab
PK: Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Mirikizumab in a Citrate-free Solution Formulation Compared to the Solution Formulation327 ± 39320 ± 36

Adverse events

Collected over Baseline Through Follow-Up (Up To 13 Weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Mirikizumab - Abdomen0/74 (0%)0/74 (0%)27/74 (36.5%)
Mirikizumab - Arm0/76 (0%)0/76 (0%)38/76 (50%)
Mirikizumab - Thigh0/76 (0%)0/76 (0%)36/76 (47.4%)
Citrate-Free Mirikizumab - Abdomen0/75 (0%)0/75 (0%)11/75 (14.7%)
Citrate-Free Mirikizumab - Arm0/75 (0%)0/75 (0%)17/75 (22.7%)
Citrate-Free Mirikizumab - Thigh0/74 (0%)0/74 (0%)17/74 (23%)
Most frequent other events
Most frequent other events
EventMirikizumab - AbdomenMirikizumab - ArmMirikizumab - ThighCitrate-Free Mirikizumab - AbdomenCitrate-Free Mirikizumab - ArmCitrate-Free Mirikizumab - Thigh
Injection site reactionGeneral disorders19/7431/7631/766/7512/7512/74
Medication errorInjury, poisoning and procedural complications6/746/765/765/755/754/74
HeadacheNervous system disorders3/742/764/761/752/751/74

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Mirikizumab - AbdomenMirikizumab - ArmMirikizumab - ThighCitrate-Free Mirikizumab - AbdomenCitrate-Free Mirikizumab - ArmCitrate-Free Mirikizumab - ThighTotal
Mean39.2 ± 12.941.9 ± 13.441.5 ± 11.940.3 ± 12.541.4 ± 12.540.8 ± 12.540.9 ± 12.6
Sex: Female, Male
Sex: Female, Male(Participants)Mirikizumab - AbdomenMirikizumab - ArmMirikizumab - ThighCitrate-Free Mirikizumab - AbdomenCitrate-Free Mirikizumab - ArmCitrate-Free Mirikizumab - ThighTotal
Female385041363835238
Male362635393739212
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Mirikizumab - AbdomenMirikizumab - ArmMirikizumab - ThighCitrate-Free Mirikizumab - AbdomenCitrate-Free Mirikizumab - ArmCitrate-Free Mirikizumab - ThighTotal
Hispanic or Latino424848454444271
Not Hispanic or Latino322728303130178
Unknown or Not Reported0100001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Mirikizumab - AbdomenMirikizumab - ArmMirikizumab - ThighCitrate-Free Mirikizumab - AbdomenCitrate-Free Mirikizumab - ArmCitrate-Free Mirikizumab - ThighTotal
American Indian or Alaska Native0200024
Asian21003410
Native Hawaiian or Other Pacific Islander0000000
Black or African American138129121367
White566262645653353
More than one race2110116
Unknown or Not Reported12123110
Region of Enrollment
Region of Enrollment(Participants)Mirikizumab - AbdomenMirikizumab - ArmMirikizumab - ThighCitrate-Free Mirikizumab - AbdomenCitrate-Free Mirikizumab - ArmCitrate-Free Mirikizumab - ThighTotal
United States747676757574450
08

Study locations

6 sites
  • Altasciences Clinical Los Angeles, Inc
    Cypress, California 90630, United States
  • LabCorp CRU, Inc.
    Daytona Beach, Florida 32117, United States
  • Clinical Pharmacology of Miami
    Miami, Florida 33014, United States
  • Qps-Mra, Llc
    Miami, Florida 33143, United States
  • Axis
    Dilworth, Minnesota 56529, United States
  • Labcorp Clinical Research LP
    Dallas, Texas 75247, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in May 2023, 5 months.

Results were first posted in Mar 2025, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2022
First posted
Dec 9, 2022
StartActual
Dec 5, 2022
Primary completionActual
May 25, 2023
CompletionActual
May 25, 2023
Results first posted
Mar 28, 2025
Last update
Mar 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05644353
Responsible party
Sponsor
First posted
Dec 9, 2022
Start date
Dec 5, 2022
Primary completion
May 25, 2023
Completion
May 25, 2023
Results posted
Mar 28, 2025
Last update
Mar 28, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirikizumab

Start the discussion